罗沙司他治疗非透析慢性肾脏病贫血的3期随机研究
这项双盲3期研究纳入2781例非透析CKD 3-5期且血红蛋白<10.0 g/dl患者,随机接受口服罗沙司他70mg每周三次或安慰剂治疗。罗沙司他组血红蛋白较基线平均变化1.75 g/dl,安慰剂组0.40 g/dl(P<0.001),并降低红细胞输注风险63%,不良事件谱与安慰剂相当。
要点
- 罗沙司他可有效提升非透析CKD患者血红蛋白水平。
- 罗沙司他降低红细胞输注风险达63%。
- 不良事件谱与安慰剂相当,最常见包括ESKD、尿路感染、肺炎和高血压。
核心结论
- 罗沙司他可有效提高非透析CKD患者血红蛋白并减少红细胞输注需求,不良事件谱与安慰剂相当。
研究设计与样本
- 双盲3期研究,纳入2781例非透析CKD 3-5期且血红蛋白<10.0 g/dl患者,按1:1随机接受口服罗沙司他70mg每周三次或安慰剂,剂量根据血红蛋白水平滴定。
主要发现
- 罗沙司他组血红蛋白较基线平均变化1.75 g/dl(95%CI 1.68-1.81),安慰剂组0.40 g/dl(95%CI 0.33-0.47),P<0.001。
- 基线超敏C反应蛋白升高的411例患者中,罗沙司他组血红蛋白平均变化1.75 g/dl(95%CI 1.58-1.92),安慰剂组0.62 g/dl(95%CI 0.44-0.80),P<0.001。
- 罗沙司他降低红细胞输注风险63%(HR 0.37,95%CI 0.30-0.44)。
- 罗沙司他组与安慰剂组最常见不良事件分别为ESKD(21.0% vs 20.5%)、尿路感染(12.8% vs 8.0%)、肺炎(11.9% vs 9.4%)和高血压(11.5% vs 9.1%)。
临床怎么用
- 对于非透析CKD 3-5期合并贫血患者,可考虑口服罗沙司他作为提升血红蛋白和减少输注的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current anemia therapies for patients with non-dialysis-dependent CKD may require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis and improves iron homeostasis. METHODS: In this double-blind phase 3 study, we randomized patients with non-dialysis-dependent CKD stages 3-5 and hemoglobin <10.0 g/dl (1:1) to thrice-weekly 70-mg oral roxadustat or placebo. Doses were titrated throughout the study based on hemoglobin levels. The primary efficacy end point was mean change from baseline in hemoglobin averaged over weeks 28-52 versus placebo, irrespective of rescue therapy use. We assessed patients for adverse events. RESULTS: The study included 2781 patients, 1393 who received roxadustat and 1388 who received placebo. Mean baseline hemoglobin was 9.1 g/dl for both groups. The mean change in hemoglobin from baseline was 1.75 g/dl (95% confidence interval [95% CI], 1.68 to 1.81) with roxadustat versus 0.40 g/dl (95% CI, 0.33 to 0.47) with placebo, (P<0.001). Among 411 patients with baseline elevated high-sensitivity C-reactive protein, mean change in hemoglobin from baseline was 1.75 g/dl (95% CI, 1.58 to 1.92) with roxadustat versus 0.62 g/dl (95% CI, 0.44 to 0.80) with placebo, (P<0.001). Roxadustat reduced the risk of red blood cell transfusion by 63% (hazard ratio, 0.37; 95% CI, 0.30 to 0.44). The most common adverse events with roxadustat and placebo, respectively, were ESKD (21.0% versus 20.5%), urinary tract infection (12.8% versus 8.0%), pneumonia (11.9% versus 9.4%), and hypertension (11.5% versus 9.1%). CONCLUSIONS: Roxadustat effectively increased hemoglobin in patients with non-dialysis-dependent CKD and reduced the need for red blood cell transfusion, with an adverse event profile comparable to that of placebo. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With CKD, Not on Dialysis, NCT02174627.
引用
- Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. J Am Soc Nephrol. 2021. PMID: 33568383. doi:10.1681/ASN.2020081150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。